We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Microfluidic Chips and Cancer Treatment

Video   Oct 18, 2016

 

Traditionally, development of treatments for diseases such as cancer has started with simple in vitro cell culture models before moving to animals. Unfortunately the majority of therapies fail, with a high associated cost, in large part due to the models neither accurately representing the complex pathophysiology of the disease nor the normal host physiology. Organs are complicated three-dimensional (3D) structures consisting of many different cell types located in a unique spatial arrangement, interweaved with extracellular matrix. In Hull, the approach has been to maintain and “interrogate” human tissue ex vivo in a continuous perfusion model, with the aim of preserving tissue’s 3D in vivo-like structure, retaining the complex cell-to-cell and cell-to-matrix interactions. Human tissues we have studied include: squamous cell carcinoma of the Head and Neck (HNSCC); colorectal carcinoma and normal tissue; ovarian carcinoma; mesothelioma, glioblastoma and heart. The limitations of this approach are the time that tissue can be maintained, and this varies for different tissue/tumour types and for each individual tumour. Up to four days almost no histopathological changes can be observed for all tissues studied and function appears unimpaired. For drug toxicity studies a 9-day incubation period was used on HNSCC to show the additive effect of using multiple chemotherapy drugs on cell death. For studying irradiation effects on colorectal and HNSCC biopsies a 4-day time frame was used; these are measured by immunohistochemical analysis (Ki67, ?H2AX, M30) of the tissue post-irradiation. As expected higher doses or fractionated delivery caused increased cell death. The major challenge now is to undertake the correlative or pseudo-clinical trials in which the tissue-on-chip treatments are compared with the patient response following delivery of the same treatment regimen. An advantage of the lab-on-a-chip approach is that simultaneously other treatments can be tested.

 
 
 
Advertisement
 

Recommended Videos

Quick guide to performing large-scale evaporation

Video

Benefit form a live demonstration of how to use industrial evaporator

WATCH NOW

2C or Not 2C: CYP2C Induction Studies for Successful Preclinical Risk Assessment (Webinar)

Video

This webinar will focus on CYP2C induction and will emphasize when to include CYP2C induction in a study, how to design the study to generate meaningful data and meet the regulatory requirements, what endpoints to measure, and how to interpret results.

WATCH NOW

Brain Organoids With Dr Christopher Esk

Video

This installment of Teach Me in 10 features Dr Christopher Esk, a postdoctoral fellow at the Institute of Molecular Biotechnology in Vienna, Austria. In this episode Esk talks about the systematic analysis of human brain tissue development using cerebral organoids.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE